Filipe Frazao / Shutterstock.com
February’s amendments to the Australian IP Act seek to increase the effectiveness and efficiency of the country’s IP system. LSIPR takes a look at the major changes and considers who will benefit most in the life sciences sector.
Just two years after one of the biggest ever shake-ups to Australian patent law—the Raising the Bar Act of 2012—further change is in store for pharmaceutical and biotechnology companies operating in Australasia.
On February 9 this year, the Australian parliament passed into law the Intellectual Property Laws Amendment Bill 2014. The act received Royal Assent on February 25.
The act makes five major amendments, four of which will affect life sciences businesses based in Australia.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at email@example.com
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Australia, IP, TRIPS, Federal Court of Australia, JSCOT, patent, patent protection,